A randomised, double blind, placebo-controlled trial of a fixed dose of N -acetyl cysteine in children with autistic disorder

Olivia M. Dean, Kylie M Gray, Kristi-Ann Villagonzalo, Seetal Dodd, Mohammadreza Mohebbi, Tanya Vick, Bruce J Tonge, Michael Berk

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Objective: Oxidative stress, inflammation and heavy metals have been implicated in the aetiology of autistic disorder. N-acetyl cysteine has been shown to modulate these pathways, providing a rationale to trial N-acetyl cysteine for autistic disorder. There are now two published pilot studies suggesting efficacy, particularly in symptoms of irritability. This study aimed to explore if N-acetyl cysteine is a useful treatment for autistic disorder. Method: This was a placebo-controlled, randomised clinical trial of 500 mg/day oral N-acetyl cysteine over 6 months, in addition to treatment as usual, in children with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of autistic disorder. The study was conducted in Victoria, Australia. The primary outcome measures were the Social Responsiveness Scale, Children's Communication Checklist-Second Edition and the Repetitive Behavior Scale-Revised. Additionally, demographic data, the parent-completed Vineland Adaptive Behavior Scales, Social Communication Questionnaire and clinician-administered Autism Diagnostic Observation Schedule were completed. Results: A total of 102 children were randomised into the study, and 98 (79 male, 19 female; age range: 3.1-9.9 years) attended the baseline appointment with their parent/guardian, forming the Intention to Treat sample. There were no differences between N-acetyl cysteine and placebo-treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups. Conclusion: This study failed to demonstrate any benefit of adjunctive N-acetyl cysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be confounders.

Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalAustralian & New Zealand Journal of Psychiatry
Volume51
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • acetyl cysteine
  • Autism
  • clinical trial
  • spectrum

Cite this

@article{19d4d9c09a594840ba9bf899b6acffd1,
title = "A randomised, double blind, placebo-controlled trial of a fixed dose of N -acetyl cysteine in children with autistic disorder",
abstract = "Objective: Oxidative stress, inflammation and heavy metals have been implicated in the aetiology of autistic disorder. N-acetyl cysteine has been shown to modulate these pathways, providing a rationale to trial N-acetyl cysteine for autistic disorder. There are now two published pilot studies suggesting efficacy, particularly in symptoms of irritability. This study aimed to explore if N-acetyl cysteine is a useful treatment for autistic disorder. Method: This was a placebo-controlled, randomised clinical trial of 500 mg/day oral N-acetyl cysteine over 6 months, in addition to treatment as usual, in children with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of autistic disorder. The study was conducted in Victoria, Australia. The primary outcome measures were the Social Responsiveness Scale, Children's Communication Checklist-Second Edition and the Repetitive Behavior Scale-Revised. Additionally, demographic data, the parent-completed Vineland Adaptive Behavior Scales, Social Communication Questionnaire and clinician-administered Autism Diagnostic Observation Schedule were completed. Results: A total of 102 children were randomised into the study, and 98 (79 male, 19 female; age range: 3.1-9.9 years) attended the baseline appointment with their parent/guardian, forming the Intention to Treat sample. There were no differences between N-acetyl cysteine and placebo-treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups. Conclusion: This study failed to demonstrate any benefit of adjunctive N-acetyl cysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be confounders.",
keywords = "acetyl cysteine, Autism, clinical trial, spectrum",
author = "Dean, {Olivia M.} and Gray, {Kylie M} and Kristi-Ann Villagonzalo and Seetal Dodd and Mohammadreza Mohebbi and Tanya Vick and Tonge, {Bruce J} and Michael Berk",
year = "2017",
month = "3",
day = "1",
doi = "10.1177/0004867416652735",
language = "English",
volume = "51",
pages = "241--249",
journal = "Australian & New Zealand Journal of Psychiatry",
issn = "0004-8674",
publisher = "SAGE Publications Ltd",
number = "3",

}

A randomised, double blind, placebo-controlled trial of a fixed dose of N -acetyl cysteine in children with autistic disorder. / Dean, Olivia M.; Gray, Kylie M; Villagonzalo, Kristi-Ann; Dodd, Seetal; Mohebbi, Mohammadreza; Vick, Tanya; Tonge, Bruce J; Berk, Michael.

In: Australian & New Zealand Journal of Psychiatry, Vol. 51, No. 3, 01.03.2017, p. 241-249.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A randomised, double blind, placebo-controlled trial of a fixed dose of N -acetyl cysteine in children with autistic disorder

AU - Dean, Olivia M.

AU - Gray, Kylie M

AU - Villagonzalo, Kristi-Ann

AU - Dodd, Seetal

AU - Mohebbi, Mohammadreza

AU - Vick, Tanya

AU - Tonge, Bruce J

AU - Berk, Michael

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objective: Oxidative stress, inflammation and heavy metals have been implicated in the aetiology of autistic disorder. N-acetyl cysteine has been shown to modulate these pathways, providing a rationale to trial N-acetyl cysteine for autistic disorder. There are now two published pilot studies suggesting efficacy, particularly in symptoms of irritability. This study aimed to explore if N-acetyl cysteine is a useful treatment for autistic disorder. Method: This was a placebo-controlled, randomised clinical trial of 500 mg/day oral N-acetyl cysteine over 6 months, in addition to treatment as usual, in children with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of autistic disorder. The study was conducted in Victoria, Australia. The primary outcome measures were the Social Responsiveness Scale, Children's Communication Checklist-Second Edition and the Repetitive Behavior Scale-Revised. Additionally, demographic data, the parent-completed Vineland Adaptive Behavior Scales, Social Communication Questionnaire and clinician-administered Autism Diagnostic Observation Schedule were completed. Results: A total of 102 children were randomised into the study, and 98 (79 male, 19 female; age range: 3.1-9.9 years) attended the baseline appointment with their parent/guardian, forming the Intention to Treat sample. There were no differences between N-acetyl cysteine and placebo-treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups. Conclusion: This study failed to demonstrate any benefit of adjunctive N-acetyl cysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be confounders.

AB - Objective: Oxidative stress, inflammation and heavy metals have been implicated in the aetiology of autistic disorder. N-acetyl cysteine has been shown to modulate these pathways, providing a rationale to trial N-acetyl cysteine for autistic disorder. There are now two published pilot studies suggesting efficacy, particularly in symptoms of irritability. This study aimed to explore if N-acetyl cysteine is a useful treatment for autistic disorder. Method: This was a placebo-controlled, randomised clinical trial of 500 mg/day oral N-acetyl cysteine over 6 months, in addition to treatment as usual, in children with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of autistic disorder. The study was conducted in Victoria, Australia. The primary outcome measures were the Social Responsiveness Scale, Children's Communication Checklist-Second Edition and the Repetitive Behavior Scale-Revised. Additionally, demographic data, the parent-completed Vineland Adaptive Behavior Scales, Social Communication Questionnaire and clinician-administered Autism Diagnostic Observation Schedule were completed. Results: A total of 102 children were randomised into the study, and 98 (79 male, 19 female; age range: 3.1-9.9 years) attended the baseline appointment with their parent/guardian, forming the Intention to Treat sample. There were no differences between N-acetyl cysteine and placebo-treated groups on any of the outcome measures for either primary or secondary endpoints. There was no significant difference in the number and severity of adverse events between groups. Conclusion: This study failed to demonstrate any benefit of adjunctive N-acetyl cysteine in treating autistic disorder. While this may reflect a true null result, methodological issues particularly the lower dose utilised in this study may be confounders.

KW - acetyl cysteine

KW - Autism

KW - clinical trial

KW - spectrum

UR - http://www.scopus.com/inward/record.url?scp=85013296117&partnerID=8YFLogxK

U2 - 10.1177/0004867416652735

DO - 10.1177/0004867416652735

M3 - Article

VL - 51

SP - 241

EP - 249

JO - Australian & New Zealand Journal of Psychiatry

JF - Australian & New Zealand Journal of Psychiatry

SN - 0004-8674

IS - 3

ER -